5.6% dividend yield forecast! 1 UK share I’d buy in October and hold for 10+ years

This little-known biotech group has hiked its dividend yield for 10 years in a row, and forecasts suggest this trend will continue through 2026!

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investor appetites for big dividend yields continue to grow thanks to inflation-driven demand for extra passive income. However, while there are countless high-yielding opportunities across the London Stock Exchange right now, most look unsustainable in the long run.

Since I don’t want to keep juggling between different income stocks over the next decade and beyond, I’m hunting for a certain type of dividend stock. Specifically, I’m looking for one that doesn’t just maintain payouts but grows them each year as well. And that’s put Bioventix (LSE:BVXP) in my sights.

Sustainable passive income

For a company to supply continuously rising dividends, it needs two key traits. The first is to have a cash-generative business model. The other is to provide a product or service that will remain in demand for decades. Bioventix seems to have both of these characteristics.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

It’s a biotech firm that specialises in manufacturing sheep monoclonal antibodies. In oversimplified terms, these are used in diagnostic medicine to detect heart disease, cancer, infertility, and potentially even Alzheimer’s if the latest ongoing tests prove successful.

Needless to say, detecting diseases isn’t likely to go out of fashion any time soon. And while there are other antibody suppliers around the world, Bioventix’s product portfolio has built a reputation for quality.

It’s undoubtedly a niche product. Yet demand continues to grow, enabling it to consistently boost revenue, earnings and free cash flow generation. So much so that the firm is entirely debt-free and has been consistently hiking its dividend for 10 years in a row.

Right now, the shares are offering a slightly better-than-average dividend yield of 4.1%. But based on analysts’ forecasts, this level of payout is set to continue growing to as high as 5.6% by 2026. And if the trends continue, it may rise even further thereafter.

Everything has its risks

Looking at the numbers, Bioventix’s track record is pretty admirable. And this has also been reflected in its stock price. Since going public in April 2014, the shares of the biotech group have climbed more than 600%!

Created with Highcharts 11.4.3Bioventix Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

However, even the best-looking businesses in the world have their weak spots. The difficulty of manufacturing monoclonal antibodies has proven to be quite a powerful barrier to entry against would-be competitors. Yet it’s also proven to be a handicap in terms of increasing production capacity.

At the same time, while diagnostic medicine is in constant demand, the types of antibodies required can be somewhat cyclical. The group’s Troponin antibodies have seen softer-than-expected sales, according to the group’s most recent interim report.

Furthermore, government changes to the headline corporation tax rate are also expected to adversely impact earnings as well as cash flows. This change is obviously out of management’s control. Nevertheless, it adds pressure to the group’s profitability and, in turn, dividends.

Despite these headwinds, I remain cautiously optimistic for this business. Its valuation comes with a small premium that invites some extra volatility. Yet given the long-term relevance of its products and the group’s impressive track record, it’s a premium I’m happy to pay. That’s why I’m planning on adding this business to my income portfolio once I have cash available.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won’t want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we’re giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Bioventix Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 high-yield dividend shares to consider buying for a retirement portfolio

Dividend shares can provide retirees with regular passive income in their golden years. Our writer picks out three with yields…

Read more »

Investing Articles

Tesla stock has halved. Could it now double – or halve again?

After a wild few months for Tesla stock, Christopher Ruane weighs some pros and cons of the investment case. Could…

Read more »

Investing Articles

Does it make sense to start buying shares as the stock market wobbles?

Does a rocky stock market make for a good or bad time to start buying shares? This writer reckons it…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£15k of passive income a year? It’s possible with the right dividend strategy!

To figure out how much dividends are needed for a lucrative passive income stream, investors must understand which strategies get…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

As US markets wobble, I’m listening to Warren Buffett!

The long career of billionaire investor Warren Buffett has included plenty of market turbulence. Here's what our writer's learnt from…

Read more »

UK money in a Jar on a background
Investing Articles

5 shares yielding over 5% to consider for a SIPP

Christopher Ruane introduces a handful of FTSE 100 and FTSE 250 shares he thinks an income-focussed SIPP investor should consider.

Read more »

Investing Articles

Here’s how an investor could invest a £20k ISA to target £1,500 of passive income per year

Can a £20,000 ISA throw off close to £30 per week on average of passive income when invested in blue-chip…

Read more »

Investing Articles

As gold hits $3,000, this FTSE 100 stock is primed for blast off

As Western institutions scramble to get as much gold as they can lay their hands on, Andrew Mackie believes this…

Read more »